BioSpace News Archive

Ligand Provides a Corporate Update and Announces May 6 th as the Date for First Quarter Earnings

Getinge, the world market leader in advanced ventilators for intensive care units, is announcing yet another ramp-up in production capacity, to 26,000 ventilators in 2020. The increase equals a growth of 160% compared to 2019, when 10,000 ventilators were produced. The demand for advanced ventilators for the intensive care

NanoMosaic L.L.C. – the leading company in protein and nucleic acid detection leveraging the power of nanoneedles for ultra-sensitive, wide dynamic range, multiplexed protein detection has announced a collaboration with Massachusetts General Hospital (MGH) in order to develop a new method for the prognostics and treatment of COVID-19 patients.

The magnetic resonance imaging market has conventionally risen on the back of an advanced imaging technique, which has boosted adoption of the high-cost hardware, and software imaging.

Transparency Market Research has published a new report titled, ‘Transcatheter Embolization and Occlusion Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

According to the report, the global microbiology culture market was valued at US$ 5.7 Bn in 2018 and is projected to expand at a CAGR of ~6% from 2019 to 2027.

The global medical imaging analysis software market is expanding at a respectable pace in recent times.

According to the report, the global blood glucose monitoring systems market was valued at US$ 15.4 Bn in 2018 and is projected to expand at a CAGR of 5.5% from 2019 to 2027. Blood glucose monitoring is used to analyze the concentration of glucose in the blood.

HEMA Biologics, LLC, (“HEMA Biologics”) today announced that the U.S. Food and Drug Administration (FDA) approved SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] as the first new bypassing agent in over 20 years for adults and adolescents (12 years of age and older) with hemophilia A and B with inhibitors.

Seres Therapeutics, Inc. , (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke, M.D., FCP, as Executive Vice President and Chief Medical Officer. Dr. von Moltke joins Seres with an extensive career that includes senior leadership positions at Alkermes, Sanofi Genzyme and Millennium Pharmaceuticals/Takeda Oncology. This press release features multimedia. View the full release here: https://www.business